Mumbai-based generic-pharmaceuticals company Lupin Pharmaceuticals Inc. has been found to have infringed on five patents related to the estrogen-free contraceptive Slynd. A Delaware federal judge ruled on Wednesday, siding with Spanish pharmaceutical company Insud Pharma and its New Jersey-based division, Exeltis USA Inc.
The judgment was in favor of all asserted claims, thereby upholding the intellectual property rights of Exeltis USA Inc. as per [Law360 coverage](https://www.law360.com/articles/1876813/lupin-infringes-exeltis-contraceptive-patents-judge-finds) of the court decision.